Anticholinergics — benztropine, trihexyphenidyl, diphenhydramine — are the treatment for two specific extrapyramidal symptoms: acute dystonia and antipsychotic-induced parkinsonism. The mechanism is restoring the dopamine-acetylcholine balance in the striatum: when D2 blockade reduces dopaminergic signaling, the cholinergic system loses its counterweight, and anticholinergics restore the equilibrium.
- Class
- Anticholinergic agents for movement disorders
- Mechanism
- Block muscarinic acetylcholine receptors in striatum → restore dopamine-ACh balance disrupted by D2 antagonism. Treats EPS, particularly dystonia and parkinsonism.
- Typical dose
- Benztropine 1-2 mg PO/IM/IV (acute); 0.5-2 mg PO BID maintenance. Trihexyphenidyl 1-5 mg BID-TID. Diphenhydramine 25-50 mg PO/IM/IV.
- Half-life
- Benztropine ~24 hours; diphenhydramine ~9 hours
- FDA indications
- Acute dystonia (IM/IV diphenhydramine or benztropine), antipsychotic-induced parkinsonism, prophylaxis with high-EPS-risk antipsychotics
- Key adverse effects
- Anticholinergic burden: dry mouth, constipation, urinary retention, blurred vision, cognitive impairment (especially elderly), confusion, tachycardia. Worsens tardive dyskinesia.
- Representative agents
- Benztropine (Cogentin), trihexyphenidyl (Artane), diphenhydramine (Benadryl)
Acute dystonia: IM/IV benztropine 1-2 mg or diphenhydramine 25-50 mg — rapidly reverses. Antipsychotic-induced parkinsonism: maintenance dosing. NOT effective for akathisia (use beta-blocker, benzodiazepine instead). Worsens TD — discontinue if TD develops.
Acute dystonia is the dramatic indication. The young man (highest risk demographic) receiving haloperidol IM develops painful sustained muscle contractions hours later — torticollis, oculogyric crisis, tongue protrusion, sometimes laryngeal dystonia threatening the airway. IM benztropine 1-2 milligrams or IV diphenhydramine 25-50 milligrams reverses the dystonia within minutes. The reversal is often dramatic. Counsel the patient afterward; provide oral prophylaxis with future antipsychotic doses.
Parkinsonism emerges over days to weeks of antipsychotic treatment. Tremor, rigidity, bradykinesia, masked facies. Treatment options: reduce the antipsychotic dose, add oral anticholinergic (benztropine 1-2 mg BID typical), or switch to a lower-EPS-risk agent. Anticholinergics work but add their own burden.
Anticholinergics treat drug-induced extrapyramidal symptoms by rebalancing the striatal dopamine-acetylcholine equilibrium that D2 blockade disrupts.
Mechanism note: Anticholinergics correct the striatal cholinergic excess behind dystonia and parkinsonism — but they do not help akathisia or TD, and their cognitive burden makes chronic use, especially in older adults, undesirable.
Anticholinergics do NOT treat akathisia. This is one of the most important things to know about EPS treatment. Akathisia — the subjective restlessness that often emerges with antipsychotics — does not improve with benztropine or its relatives, and the anticholinergic burden adds to side effects without addressing the akathisia. First-line for akathisia is propranolol; benzodiazepine is a second option.
Anticholinergics WORSEN tardive dyskinesia. The mechanism is upregulated dopamine supersensitivity from chronic D2 blockade; anticholinergic activity unmasks the supersensitivity. If TD develops in a patient on chronic anticholinergic, discontinue the anticholinergic — that's part of TD management, along with minimizing antipsychotic exposure and considering VMAT2 inhibitors.
For acute dystonia: anticholinergic, immediately. For parkinsonism: anticholinergic, sometimes. For akathisia or TD: NOT anticholinergic.